Castration-resistant prostate cancer, or CRPC, is an aggressive stage of prostate cancer
(PCa) in which PCa cells invade nearby or other parts of the body. When a patient with PCa …

5008 Background: Androgen receptor (AR) signaling is an important growth mechanism in
mCRPC, providing the rationale for treatment with AR axis inhibitors such as ENZ and AAP …

BACKGROUND Two androgen receptor (AR)‐targeted therapies, enzalutamide and
abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of …

What's known on the subject? and What does the study add? Castration resistance has
been appreciated for decades, and several mechanisms theorising on this effect have been …

5066 Safety and efficacy of Everolimus (E), bevacizumab (B), and docetaxel (D) for
castration resistant prostate cancer (CRPC) Background: Based on studies suggesting co …

The landscape of castration-resistant prostate carcinoma has changed completely in the last
few years, with the approval of four new agents with proven benefit in overall survival …

Until recently, the only systemic regimen known to impact overall survival (OS) in men with
symptomatic metastatic castration-resistant prostate cancer (mCRPC) was a taxane-based …

BACKGROUND Most prostate cancer‐related deaths occur in patients with castration‐
resistant prostate cancer (CRPC). Recent preclinical and clinical studies have identified …

Background Prostate cancer that recurs after initial treatment inevitably progresses to
castration‐resistant prostate cancer (CRPC), the lethal stage of the disease. Despite …

Various molecular mechanisms have been implicated in the progression from hormone‐
sensitive to castration‐resistant prostate cancer (CRPC). Novel targeted agents to treat …